Bristol Myers' Caforio: CELMoDs have potential to replace Revlimid and Pomalyst as blockbusters start to lose exclusivity

Paul Schloesser

Associate Editor

Staring down the inevitable loss of exclusivity over the next few years for Bristol Myers Squibb’s blockbuster multiple myeloma drugs Revlimid and Pomalyst, the Big …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers' Caforio: CELMoDs have potential to replace Revlimid and Pomalyst as blockbusters start to lose exclusivity

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Bris­tol My­er­s' Caforio: CELMoDs have po­ten­tial to re­place Revlim­id and Po­m­a­lyst as block­busters start to lose ex­clu­siv­i­ty

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Bristol Myers' Caforio: CELMoDs have potential to replace Revlimid and Pomalyst as blockbusters start to lose exclusivity

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?